| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Atara Biotherapeutics, Inc. (ATRA) has 3 insiders with recent SEC Form 4 filings, including 0 buys and 24 sells. ATRA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.32M | $13.97M | - | |
| CEO | 143.1K | $1.51M | - | |
| Other | 52.0K | $549.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 18, 2018 | Gallagher Carol Giltner | Director | Sell | 2,500 | $44.78 | $111,944.00 | -1.1% | |
| Jun 6, 2018 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 8,800 | $48.56 | $427,288.00 | -1.1% | |
| May 22, 2018 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 8,800 | $51.74 | $455,313.00 | -1.2% | |
| May 18, 2018 | Clark Mitchall G. | EVP &Chief R &Qa Officer | Sell | 25,860 | $50.03 | $1,293,775.80 | -19.3% | |
| May 16, 2018 | Gallagher Carol Giltner | Director | Sale+OE | 273 | $46.06 | $12,574.38 | -0.2% | |
| May 16, 2018 | Clark Mitchall G. | EVP &Chief R &Qa Officer | Sale+OE | 4,647 | $46.06 | $214,025.88 | -1.7% | |
| May 15, 2018 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sale+OE | 25,775 | $45.30 | $1,167,480.42 | -2.5% | |
| May 15, 2018 | Porter Derrell | SVP, Head Of Global Commercial | Sale+OE | 16,334 | $45.02 | $735,356.68 | -56.6% | |
| May 14, 2018 | Fust Matthew K77 | Director | Sale+OE | 12,286 | $43.57 | $535,301.02 | -38.3% | |
| May 10, 2018 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 8,800 | $39.85 | $350,637.00 | -1.2% |